Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

NIZATIDINE 300 MG CAPSULE

Nizatidine
$0.7988per EA

Strength

300 mg/1

Manufacturer

Actavis Pharma, Inc.

NDC

00591313830

Classification

Generic

Dosage Form

CAPSULE

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

NIZATIDINE

Approval Type

Generic (ANDA)

FDA Application

ANDA075616

On Market Since

7/9/2002

Pharmacological Classes

Histamine H2 Receptor Antagonists
Histamine-2 Receptor Antagonist

Price History

1W

0.0%

1M

0.0%

3M

+2.6%

6M

+77.2%

1Y

+77.2%

3Y

+77.2%

5Y

+77.2%

All

+30.1%

Generic Alternatives

Save up to 27%

1 alternative • Same active ingredient

NIZATIDINE 300 MG CAPSULE
Generic
55111031130•Dr. Reddy's Laboratories Inc.
$0.5821
Save 27%

Related Drugs

Same classification

FAMOTIDINE 20 MG TABLET
Generic
63739064510•McKesson
$0.0303
per EA
FAMOTIDINE 20 MG TABLET
Generic
00172572860•Teva Pharmaceuticals USA Inc.
$0.0310
per EA
FAMOTIDINE 20 MG TABLET
Generic
00172572870•Teva Pharmaceuticals USA Inc.
$0.0310
per EA
FAMOTIDINE 20 MG TABLET
Generic
00172572880•Teva Pharmaceuticals USA Inc.
$0.0310
per EA
FAMOTIDINE 20 MG TABLET
Generic
00904719306•Major Pharmaceuticals
$0.0310
per EA
FAMOTIDINE 20 MG TABLET
Generic
00904719361•Major Pharmaceuticals
$0.0310
per EA
FAMOTIDINE 20 MG TABLET
Generic
31722001701•Camber Pharmaceuticals Inc.
$0.0310
per EA
FAMOTIDINE 20 MG TABLET
Generic
31722001710•Camber Pharmaceuticals Inc.
$0.0310
per EA
FAMOTIDINE 20 MG TABLET
Generic
50268029915•AvPAK
$0.0310
per EA
FAMOTIDINE 20 MG TABLET
Generic
55111011901•Dr. Reddy's Laboratories Inc.
$0.0310
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy